Degree of atherosclerosis predicts short-term commitment for smoking cessation therapy

Objectives: Telemedicine appears to be a promising tool for healthcare professionals to deliver remote care to patients with cardiovascular diseases especially during the COVID-19 pandemic. We aimed in this study to evaluate the value of telemedicine added to the short-term medical care of acute ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI).Methods: Two hundred acute STEMI patients after primary PCI were randomly divided into two groups. One hundred patients in group A (study group) received a monthly videoconferencing teleconsultation using a smartphone application for 3 months starting 1 week after discharge and at least a single face-to-face (F2F) clinic visit. We reviewed in each virtual visit the symptoms of patients, adherence to healthy lifestyle measures, medications, smoking cessation, and cardiac rehabilitation. Group B (control group) included 100 patients who received at least a single F2F clinic visit in the first 3 months after discharge. Both groups were interviewed after 4 months from discharge for major adverse cardiac events (MACE), adherence to medications, smoking cessation, and cardiac rehabilitation. A survey was done to measure the satisfaction of patients with telemedicine.Results: There was no significant difference between both groups in MACE and their adherence to aspirin, P2Y12 inhibitor, and beta-blockers. However, group A patients had better adherence to statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, smoking cessation, and cardiac rehabilitation. Sixty-one percent of patients stated that these videoconferencing teleconsultations were as good as the clinic visits, while 87% of patients were satisfied with telemedicine.Conclusions: Telemedicine may provide additional benefit to the short-term regular care after primary PCI to STEMI patients through videoconferencing teleconsultations by increasing their adherence to medications and healthy lifestyle measures without a significant difference in the short-term MACE. These virtual visits gained a high level of satisfaction among the patients.

Download Full-text

Smoking cessation therapy to reduce COPD costs?

PharmacoEconomics & Outcomes News ◽

10.1007/bf03275656 ◽

2000 ◽

Vol 289 (1) ◽

pp. 6-6

Keyword(s):

Smoking Cessation ◽

Smoking Cessation Therapy

Download Full-text

Smoking Cessation Therapy is a Cost-Effective Intervention to Avoid Tooth Loss in Subjects With Periodontitis – An Economic Evaluation

10.21203/rs.3.rs-228724/v1 ◽

2021 ◽

Author(s):

Maria Luisa Silveira Souto ◽

Fernanda Campos Almeida Carrer ◽

Mariana Minatel Braga ◽

Cláudio Mendes Pannuti

Keyword(s):

Smoking Cessation ◽

Cost Effectiveness ◽

Oral Health ◽

Incremental Cost ◽

Tooth Loss ◽

Cost Effective ◽

Cost Utility ◽

Health Related ◽

Per Oral ◽

Smoking Cessation Therapy

Abstract Background: Smokers present a higher prevalence and severity of periodontitis and, consequently, higher prevalence of tooth loss. Smoking cessation improves the response to periodontal treatment and reduces tooth loss. So, the aim of this study was evaluated the efficiency in resources allocation when implementing smoking cessation therapy vs. its non-implementation in smokers with periodontitis. Methods: We adopted the Brazilian public system perspective to determine the incremental cost-effectiveness (cost per tooth loss avoided) and cost-utility (cost per oral-related quality-adjusted life-year ([QALY] gained) of implementing smoking cessation therapy. Base-case was defined as a 48 years-old male subject and horizon of 30 years. Effects and costs were combined in a decision analytic modeling framework to permit a quantitative approach aiming to estimate the value of the consequences of smoking cessation therapy adjusted for their probability of occurrence. Markov models were carried over annual cycles. Sensitivity analysis tested methodological assumptions. Results: Implementation of smoking cessation therapy had an average incremental cost of U$60.58 per tooth loss avoided and U$4.55 per oral related-QALY gained. Considering uncertainties, the therapy could be cost-effective in the most part of simulated cases, even being cheaper and more effective in 53% of cases in which the oral-health related outcome is used as effect. Considering a willingness-to-pay of US$100 per health effect, smoking cessation therapy was cost-effective, respectively, in 81% and 100% of cases in cost-utility and cost-effectiveness analyses. Conclusions: Implementation of smoking cessation therapy may be cost-effective, considering the avoidance of tooth loss and oral health-related consequences to patients.

Download Full-text

The Examination of the Acute Vascular Changes after Short-Term Smoking Cessation Using Second Derivative of Photoplethysmogram in the Adult Men

Korean Journal of Family Practice ◽

10.21215/kjfp.2017.7.1.42 ◽

2017 ◽

Vol 7 (1) ◽

pp. 42-48

Author(s):

Eun-Sook Park ◽

Seock-Hwan Lee ◽

Hyunsug Bae ◽

Joon-Woo Kim ◽

Jong-Myung Park

Keyword(s):

Smoking Cessation ◽

Second Derivative ◽

Vascular Changes ◽

Short Term ◽

Adult Men

Download Full-text

Smoking cessation in severe mental illness: combined long-term quit rates from the UK SCIMITAR trials programme

The British Journal of Psychiatry ◽

10.1192/bjp.2019.192 ◽

2019 ◽

pp. 1-3 ◽

Cited By ~ 2

Author(s):

Simon Gilbody ◽

Emily Peckham ◽

Della Bailey ◽

Catherine Arundel ◽

Paul Heron ◽

...

Keyword(s):

Mental Illness ◽

Smoking Cessation ◽

Severe Mental Illness ◽

Short Term ◽

Cessation Intervention ◽

Term Trial ◽

Short And Long Term ◽

The Uk ◽

Full Trial

Summary Smoking contributes to health inequalities for people with severe mental illness (SMI). Although smoking cessation interventions are effective in the short term, there are few long-term trial-based estimates of abstinence. The SCIMITAR trials programme includes the largest trial to date of a smoking cessation intervention for people with SMI, but this was underpowered to detect anticipated long-term quit rates. By pooling pilot and full-trial data we found that quit rates were maintained at 12 months (OR = 1.67, 95% CI 1.02–2.73, P = 0.04). Policymakers can now be confident that bespoke smoking cessation interventions produce successful short- and long-term quitting.

Download Full-text